Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-ββ1 inhibition. (December 2011)
- Record Type:
- Journal Article
- Title:
- Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-ββ1 inhibition. (December 2011)
- Main Title:
- Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-ββ1 inhibition
- Authors:
- Yan, Alan
Avraham, Tomer
Zampell, Jamie C
Haviv, Yosef S
Weitman, Evan
Mehrara, Babak J - Abstract:
- Aims: Recent studies have demonstrated that augmentation of lymphangiogenesis and tissue engineering hold promise as a treatment for lymphedema. The purpose of this study was to determine whether adipose-derived stem cells (ASCs) can be used in lymphatic tissue-engineering by altering the balance between pro- and anti-lymphangiogenic cytokines.Materials & methods: ASCs were harvested and cultured in media with or without recombinant VEGF-C for 48 h. ASCs were then implanted in mice using Matrigel plugs. Additional groups of animals were implanted with ASCs transfected with a dominant-negative TGF-ββ1 receptor-II adenovirus with or without VEGF-C stimulation, since TGF-ββ1 has been shown to have potent antilymphangiogenic effects. Lymphangiogenesis, lymphatic differentiation and cellular proliferation were assessed.Results: Stimulation of ASCs with VEGF-C in vitro significantly increased expression of VEGF-A, VEGF-C and Prox-1. ASCs stimulated with VEGF-C prior to implantation induced a significant (threefold increase) lymphangiogenic response as compared with control groups (unstimulated ASCs or empty Matrigel plugs; p < 0.01). This effect was significantly potentiated when TGF-ββ1 signaling was inhibited using the dominant-negative TGF-ββ1 receptor-II virus (4.5-fold increase; p < 0.01). Stimulation of ASCs with VEGF-C resulted in a marked increase in the number of donor ASCs (twofold; p < 0.01) and increased the number of proliferating cells (sevenfold; p < 0.01)Aims: Recent studies have demonstrated that augmentation of lymphangiogenesis and tissue engineering hold promise as a treatment for lymphedema. The purpose of this study was to determine whether adipose-derived stem cells (ASCs) can be used in lymphatic tissue-engineering by altering the balance between pro- and anti-lymphangiogenic cytokines.Materials & methods: ASCs were harvested and cultured in media with or without recombinant VEGF-C for 48 h. ASCs were then implanted in mice using Matrigel plugs. Additional groups of animals were implanted with ASCs transfected with a dominant-negative TGF-ββ1 receptor-II adenovirus with or without VEGF-C stimulation, since TGF-ββ1 has been shown to have potent antilymphangiogenic effects. Lymphangiogenesis, lymphatic differentiation and cellular proliferation were assessed.Results: Stimulation of ASCs with VEGF-C in vitro significantly increased expression of VEGF-A, VEGF-C and Prox-1. ASCs stimulated with VEGF-C prior to implantation induced a significant (threefold increase) lymphangiogenic response as compared with control groups (unstimulated ASCs or empty Matrigel plugs; p < 0.01). This effect was significantly potentiated when TGF-ββ1 signaling was inhibited using the dominant-negative TGF-ββ1 receptor-II virus (4.5-fold increase; p < 0.01). Stimulation of ASCs with VEGF-C resulted in a marked increase in the number of donor ASCs (twofold; p < 0.01) and increased the number of proliferating cells (sevenfold; p < 0.01) surrounding the Matrigel. ASCs stimulated with VEGF-C expressed podoplanin, a lymphangiogenic cell marker, whereas unstimulated cells did not.Conclusion: Short-term stimulation of ASCs with VEGF-C results in increased expression of VEGF-A, VEGF-C and Prox-1 in vitro and is associated with a marked increase lymphangiogenic response after in vivo implantation. This lymphangiogenic response is significantly potentiated by blocking TGF-ββ1 function. Furthermore, stimulation of ASCs with VEGF-C markedly increases cellular proliferation and cellular survival after in vivo implantation and stimulated cells express podoplanin, a lymphangiogenic cell marker. … (more)
- Is Part Of:
- Future oncology. Volume 7:Number 12(2011)
- Journal:
- Future oncology
- Issue:
- Volume 7:Number 12(2011)
- Issue Display:
- Volume 7, Issue 12 (2011)
- Year:
- 2011
- Volume:
- 7
- Issue:
- 12
- Issue Sort Value:
- 2011-0007-0012-0000
- Page Start:
- 1457
- Page End:
- 1473
- Publication Date:
- 2011-12
- Subjects:
- adipose-derived stem cells -- antilymphangiogenic -- lymphangiogenesis -- TGF-ββ -- tissue engineering -- VEGF-C
Oncology -- Periodicals
616.99405 - Journal URLs:
- http://www.futuremedicine.com/loi/fon ↗
http://www.futuremedicine.com/ ↗ - DOI:
- 10.2217/fon.11.121 ↗
- Languages:
- English
- ISSNs:
- 1479-6694
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4060.610420
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 16683.xml